Capricor Therapeutics Reported Positive Deramiocel Results

The company presented new data from its study on a treatment for upper limb impairment in Duchenne muscular dystrophy.

Updated on Oct. 5, 2026 in Biotech

Capricor Therapeutics Reported Positive Deramiocel Results

Live Poll

Should the government prioritize fast-track approval for new medical treatments for rare diseases?

Capricor Therapeutics has shared positive results from the HOPE-3 study, which evaluated the efficacy of Deramiocel. Patients who transitioned from a placebo to the treatment saw a 76% reduction in the rate of upper limb decline.

Why it matters

Duchenne muscular dystrophy is a progressive condition caused by the absence of functional dystrophin in muscle cells. Providing effective therapies to slow functional decline remains a critical need for those living with the disease.

The HOPE-3 study randomized 106 patients to receive intravenous Deramiocel or a placebo every three months. Researchers utilized the PUL 2.0 total score to measure upper limb function in the 98 patients who entered the open-label extension.

The players

Capricor Therapeutics

Based in San Diego, this biotechnology company focuses on the development of cell and exosome-based therapeutics for the treatment of rare diseases.

World Muscle Society

This international medical organization promotes the exchange of knowledge and professional advancement regarding muscle disorders and neuromuscular research.

FDA

The Food and Drug Administration is the federal agency responsible for regulating biologics and approving new medical treatments for public use.

The details

The positive data were presented at the 31st Annual Congress of the World Muscle Society and have been submitted to the FDA as part of an amendment to the company's Biologics License Application. One-year results for the HOPE-3 trial were previously published in The Lancet in July 2026.

July 2026: One-year study results were published in The Lancet.
October 5, 2026: Data were presented at the World Muscle Society Congress.
October 7, 2026: A webinar is scheduled to discuss the clinical data.
November 22, 2026: The FDA PDUFA target action date for the Deramiocel application.

The Tech Race

This development represents a significant step in the broader shift toward cell-based therapies for neuromuscular disorders. It follows the regulatory framework set by the FDA's Biologics License Application process to ensure safety and efficacy.

For individuals and families affected by Duchenne muscular dystrophy, these results provide insight into potential future treatment options. Patients and caregivers should continue monitoring the FDA review process ahead of the November 22, 2026, target date.

The takeaway

Advancements in clinical trials offer hope for slowing the progression of rare muscular disorders. Families impacted by such conditions should consult with their medical providers to understand how emerging data may influence long-term care plans.